FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022609995> ?p ?o ?g. }

• W2022609995 endingPage "636" @default.
• W2022609995 startingPage "630" @default.
• W2022609995 abstract "To evaluate, both polysomnographically and by subjective scales, the efficacy and safety profile of pramipexole for restless legs syndrome (RLS) via a 3-week, double-blind, placebo-controlled, parallel-group, dose-ranging study.At baseline and after 3 weeks, periodic limb movements (PLM) and sleep parameters were assessed by polysomnography, and patients self-assessed their sleep disturbance and overall RLS severity using the international RLS study group rating scale (IRLS). Four pramipexole doses were evaluated: 0.125, 0.25, 0.50, and 0.75mg/d. Data from 107 patients were included in the intent-to-treat (ITT) analysis.For pramipexole recipients, the primary outcome measure, PLM per hour in bed asleep or awake (the PLM index, or PLMI), decreased by a median of -26.55 to -52.70 depending on dosage group, vs. -3.00 for placebo (p<0.01 or 0.001 for each group vs. placebo; Wilcoxon-Mann-Whitney test). Improvements in the secondary endpoints of PLM while asleep and while awake were also significantly superior for pramipexole. At 3 weeks, all pramipexole doses reduced the median for PLM while asleep to levels considered normal (<5PLM/h). Except for delta-sleep time and awakenings/arousals, sleep parameters remained unchanged or favored pramipexole. Median sleep latency was reduced by -5.00 to -11.75min in the pramipexole groups, vs. -2.00 for placebo (p<0.05 for all groups except 0.25mg/d). Median total sleep time increased by 25.75-66.75min, vs. 25.50 (p<0.05 for 0.50mg/d), and median time in stages 2-4/rapid eye movement (REM) sleep increased by 37.00-68.00min, vs. 26.75 (p<0.05 for 0.50mg/d). By subjective IRLS ratings, all pramipexole doses were significantly superior to placebo. Safety analysis demonstrated no dose-dependent increase in adverse events, and no drug-related increase in daytime somnolence was observed.Pramipexole is effective and well tolerated in RLS, most notably among objective measures, for reducing PLM and decreasing sleep latency. Although other sleep parameters showed lesser, usually insignificant change, patients' subjective ratings of RLS severity and sleep disturbance were significantly improved (p0.0023)." @default.
• W2022609995 created "2016-06-24" @default.
• W2022609995 creator A5011435481 @default.
• W2022609995 creator A5027633068 @default.
• W2022609995 creator A5035062717 @default.
• W2022609995 creator A5039186611 @default.
• W2022609995 creator A5047266894 @default.
• W2022609995 creator A5059062817 @default.
• W2022609995 creator A5077856437 @default.
• W2022609995 creator A5078244275 @default.
• W2022609995 date "2009-06-01" @default.
• W2022609995 modified "2023-10-16" @default.
• W2022609995 title "A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: Polysomnographic evaluation of periodic leg movements and sleep disturbance" @default.
• W2022609995 cites W1967749743 @default.
• W2022609995 cites W1969281286 @default.
• W2022609995 cites W1969979542 @default.
• W2022609995 cites W197066864 @default.
• W2022609995 cites W1977809194 @default.
• W2022609995 cites W1982104709 @default.
• W2022609995 cites W1993919473 @default.
• W2022609995 cites W2012065969 @default.
• W2022609995 cites W2023740305 @default.
• W2022609995 cites W2034430472 @default.
• W2022609995 cites W2053297910 @default.
• W2022609995 cites W2058182118 @default.
• W2022609995 cites W2072667894 @default.
• W2022609995 cites W2091605545 @default.
• W2022609995 cites W2095827022 @default.
• W2022609995 cites W2103440392 @default.
• W2022609995 cites W2103727537 @default.
• W2022609995 cites W21164167 @default.
• W2022609995 cites W2120007799 @default.
• W2022609995 cites W2128833191 @default.
• W2022609995 cites W2408799309 @default.
• W2022609995 cites W4247259435 @default.
• W2022609995 cites W96689107 @default.
• W2022609995 doi "https://doi.org/10.1016/j.sleep.2008.05.014" @default.
• W2022609995 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19171500" @default.
• W2022609995 hasPublicationYear "2009" @default.
• W2022609995 type Work @default.
• W2022609995 sameAs 2022609995 @default.
• W2022609995 citedByCount "38" @default.
• W2022609995 countsByYear W20226099952012 @default.
• W2022609995 countsByYear W20226099952013 @default.
• W2022609995 countsByYear W20226099952014 @default.
• W2022609995 countsByYear W20226099952015 @default.
• W2022609995 countsByYear W20226099952016 @default.
• W2022609995 countsByYear W20226099952017 @default.
• W2022609995 countsByYear W20226099952018 @default.
• W2022609995 countsByYear W20226099952019 @default.
• W2022609995 countsByYear W20226099952021 @default.
• W2022609995 countsByYear W20226099952022 @default.
• W2022609995 countsByYear W20226099952023 @default.
• W2022609995 crossrefType "journal-article" @default.
• W2022609995 hasAuthorship W2022609995A5011435481 @default.
• W2022609995 hasAuthorship W2022609995A5027633068 @default.
• W2022609995 hasAuthorship W2022609995A5035062717 @default.
• W2022609995 hasAuthorship W2022609995A5039186611 @default.
• W2022609995 hasAuthorship W2022609995A5047266894 @default.
• W2022609995 hasAuthorship W2022609995A5059062817 @default.
• W2022609995 hasAuthorship W2022609995A5077856437 @default.
• W2022609995 hasAuthorship W2022609995A5078244275 @default.
• W2022609995 hasConcept C126322002 @default.
• W2022609995 hasConcept C142724271 @default.
• W2022609995 hasConcept C1513209611 @default.
• W2022609995 hasConcept C15744967 @default.
• W2022609995 hasConcept C204787440 @default.
• W2022609995 hasConcept C27081682 @default.
• W2022609995 hasConcept C2776312127 @default.
• W2022609995 hasConcept C2776750294 @default.
• W2022609995 hasConcept C2777446050 @default.
• W2022609995 hasConcept C2778205975 @default.
• W2022609995 hasConcept C2778664715 @default.
• W2022609995 hasConcept C2779134260 @default.
• W2022609995 hasConcept C2779734285 @default.
• W2022609995 hasConcept C2779989193 @default.
• W2022609995 hasConcept C2781210498 @default.
• W2022609995 hasConcept C2781326671 @default.
• W2022609995 hasConcept C2781433485 @default.
• W2022609995 hasConcept C2991744798 @default.
• W2022609995 hasConcept C42219234 @default.
• W2022609995 hasConcept C63759246 @default.
• W2022609995 hasConcept C71924100 @default.
• W2022609995 hasConcept C98274493 @default.
• W2022609995 hasConceptScore W2022609995C126322002 @default.
• W2022609995 hasConceptScore W2022609995C142724271 @default.
• W2022609995 hasConceptScore W2022609995C1513209611 @default.
• W2022609995 hasConceptScore W2022609995C15744967 @default.
• W2022609995 hasConceptScore W2022609995C204787440 @default.
• W2022609995 hasConceptScore W2022609995C27081682 @default.
• W2022609995 hasConceptScore W2022609995C2776312127 @default.
• W2022609995 hasConceptScore W2022609995C2776750294 @default.
• W2022609995 hasConceptScore W2022609995C2777446050 @default.
• W2022609995 hasConceptScore W2022609995C2778205975 @default.
• W2022609995 hasConceptScore W2022609995C2778664715 @default.
• W2022609995 hasConceptScore W2022609995C2779134260 @default.
• W2022609995 hasConceptScore W2022609995C2779734285 @default.
• W2022609995 hasConceptScore W2022609995C2779989193 @default.

• next